Evaluation of the Clinical Impact of Ultra Fast-Track in Patients Undergoing Cardiac Surgery (CARDU-FAST)

September 30, 2023 updated by: Lourdes Montero Cruces, Hospital San Carlos, Madrid

Evaluation of the Clinical Impact of Ultra Fast-Track in Patients Undergoing Cardiac Surgery Versus Conventional Extubation (CARDU-FAST)

Single center randomized clinical trial. The main aim is to demonstrate the superiority at the clinical level of the ultra fast-track programs versus conventional early postoperative extubation in patients undergoing cardiac surgery.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

The study is aimed to compare clinical superiority of ultra fast-track versus conventional early postoperative extubation in patients undergoing cardiac surgery in our center. The estimated sample size is 382 patients. They will be randomized 1:1 to any of the two arms of the study (ultra fast-track vs. fast-track). The randomization will be stratified according the type of surgery performed. The period of recruitment will start in January 2023 and is supposed to finish by December 2024 or earlier. The main outcomes of the study will be measured 1 year after the procedure.

Study Type

Interventional

Enrollment (Estimated)

382

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Madrid, Spain, 28040
        • Recruiting
        • Hospital Clínico San Carlos
        • Contact:
          • Lourdes Montero Cruces

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients over 18 years of age.
  • Patients with valvular, coronary or aortic heart disease with an indication for major cardiac surgery.
  • The patient's desire to participate in the clinical trial verified by signing the informed consent.

Exclusion Criteria:

  1. Pregnancy.
  2. Emergent surgery or cardiorespiratory arrest.
  3. Patient in preoperative cardiogenic shock, or in need of high-dose vasoactive support.
  4. Aortic arch procedures.
  5. Procedures in which hypothermia < 28ºC of temperature is expected during the intervention.
  6. Minor cardiac surgery procedures.
  7. Procedures with minimally invasive techniques without extracorporeal circulation (Transcatheter aortic valve implantation, Transcatheter mitral valve implantation, Minimally invasive mitral valve repair (TOP-Mini), Totally thoracoscopic MAZE procedure, Minimally invasive direct coronary artery bypass grafting).
  8. Implantation of circulatory assistance devices or ECMO (extracorporeal membrane oxygenation).
  9. Active endocarditis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ultra fast-track
Patients are extubated in the operating room after the procedure
Patients are extubated in the operating room
Active Comparator: Conventional extubation
Patients are extubated in the intensive unit care
Patients are extubated in the operating room

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determine the effect of Ultra Fast-track
Time Frame: 1 year
Determine the effect of Ultra Fast-track on the occurrence of the composite outcome composed of all-cause mortality, respiratory complications (prolonged intubation over 24h, reintubation, or pneumonia) and AKIN-III (acute renal failure) in patients undergoing ultra fast-track and patients with conventional postoperative extubation.
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Procedural resources conpsumption
Time Frame: 1 year
Comparison of operating room occupancy time (minutes), ICU stay and overall postoperative stay (days).
1 year
Differences in the need for high flow nasal oxygen therapy or non-invasive ventilation for >24h.
Time Frame: 1 year
Comparison of the need for high flow nasal oxygen therapy or non-invasive ventilation for >24h after the procedure.
1 year
Differences in major bleeding or life-threatening bleeding.
Time Frame: 1 year
Comparison of the event of major bleeding or life-threatening bleeding (VARC 2 definition).
1 year
Differences in neurological complication
Time Frame: 1 year
Comparison of the incidence of neurological complication after the procedure.
1 year
Differences in the incidence of acute myocardial infarction.
Time Frame: 1 year
Comparison of the incidence of acute myocardial infarction after the procedure.
1 year
Differences in the incidence of heart reoperation
Time Frame: 1 year
Comparison of the reoperation rate after the procedure.
1 year
Differences in the incidence of infections rate.
Time Frame: 1 year
Comparison of the incidence of infection that requires intravenous antibiotic therapy, which causes an increase in hospital stay or engage patient's life.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lourdes Montero Cruces, Hospital San Carlos, Madrid

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 22, 2023

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

January 20, 2023

First Submitted That Met QC Criteria

January 30, 2023

First Posted (Actual)

January 31, 2023

Study Record Updates

Last Update Posted (Actual)

October 3, 2023

Last Update Submitted That Met QC Criteria

September 30, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 22/720-EC_X

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Surgery

Clinical Trials on Ultra Fast-track

3
Subscribe